Evidence map›Paper›PMID 41931634›Full record

ArticleJCI insight2026

TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma.

Jacqueline Plesset, Meredith L Stone, John C McVey, Heather Coho, Kelly Markowitz, Kayjana Coho, Jesse Lee, Anna S Thickens, Devora Delman, Gregory L Beatty

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jacqueline PlessetAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Meredith L StoneAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
John C McVeyAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Heather CohoAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kelly MarkowitzAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kayjana CohoAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jesse LeeAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Anna S ThickensAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Devora DelmanAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Gregory L BeattyAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

Targeting the liver for immunotherapy in pancreatic cancerR01CA197916 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Gregory L Beatty · 2016 to 2026
$3.7M
SURGICAL ONCOLOGY RESEARCH TRAINING PROGRAM AT PENNT32CA251063 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Ronald P. Dematteo · 2020 to 2026
$2.6M
Mechanisms and therapeutic targets of cancer metastasisR01CA245323 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BEATTY, GREGORY L · 2020 to 2024
$1.8M
NCI NIH HHS R01 CA197916NCI NIH HHS R01 CA245323NCI NIH HHS T32 CA251063
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) shows profound resistance to immunotherapy due to its immunosuppressive tumor microenvironment. Here, we studied the relationship between T cell infiltration and innate immune signaling in PDAC, identifying TLR2 as a key regulator of T cell exclusion. TLR2 expression correlated with T cell infiltration in both human and mouse PDAC tumors. Using genetic KO models and adoptive T cell transfer experiments, we found that TLR2 expression in both T cells and non-T cells contributes to T cell exclusion in PDAC. Notably, successful infiltration of adoptively transferred tumor-specific T cells required TLR2 deletion in both the transferred cells and the recipient host. The therapeutic implications of these findings are demonstrated through both genetic deletion and pharmacological inhibition of TLR2 using AAV-mediated and antibody-based approaches in murine models, resulting in decreased tumor growth and extended survival. Collectively, these findings identify TLR2 as a key modulator of T cell trafficking and immune suppression within the PDAC microenvironment, suggesting its potential as a therapeutic target for improving treatment outcomes.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsT-LymphocytesToll-Like Receptor 2AnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMiceMice, Inbred C57BLMice, KnockoutSignal TransductionTumor MicroenvironmentTLR2 protein, humanTlr2 protein, mouseToll-Like Receptor 2CancerCancer immunotherapyImmunologyInflammationOncologyT cells

Identifiers

PMID41931634
PMCPMC13232717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.